India's largest drug maker, Ranbaxy Laboratories bounced back 15 per cent to close at Rs 470.70 after the company's CEO, Malvinder Singh clarified that the deal with Japan's Daiichi Sankyo remains on track.

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>He also promised all the information required for a probe by the US authorities. The stock made an intraday high of Rs 476.60 and a low of Rs 430. 
</p><p class='TableClas'>The counter witnessed volumes of 70,46,635 shares, which is about five times the two-week average. The stock has corrected by 12.35 per cent in the last one week. </P></p><p class='TableClas'></p></table>


Ranbaxy rises following management clarification

DALAL STREET SPIKES

More From This Section

Idea shares fall after Q3 earnings disappoint

BofA-Merrill raises Indiabulls to 'buy', stock gains

Suzlon stocks jump 17% on CDR approval

Maruti Suzuki rallies as Q3 profit beats analyst's estimates

Explore News